Form 4: Veracyte CEO Marc Stapley Reports Routine Tax Withholding on RSU Vesting
Insider Transaction Report
Veracyte CEO Marc Stapley reported the withholding of 9,399 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units, not a discretionary sale.
Summary
- Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), reported a transaction on June 2, 2025, as detailed in a Form 4 filing.
- The transaction involved the disposition of 9,399 shares of Veracyte common stock at a price of $26.74 per share.
- This disposition was specifically for tax withholding purposes in connection with the vesting of Restricted Stock Units (RSUs) and does not represent a sale by Mr. Stapley.
- The shares withheld covered tax obligations for RSUs granted on June 1, 2021 (2,926 units), March 3, 2022 (3,534 units), March 6, 2023 (4,877 units), and March 6, 2024 (7,170 units).
- Following this transaction, Mr. Stapley beneficially owns 349,237 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine tax withholding event for RSU vesting, which is a neutral event from an investment perspective as it is not a discretionary sale by the insider.
Positives
- The transaction is a routine tax withholding event, not a discretionary sale of shares by the CEO, which typically indicates continued confidence in the company.
- The event signifies the vesting of previously granted Restricted Stock Units (RSUs), confirming the executive's continued long-term incentive compensation and alignment with shareholder interests.
Negatives
- No direct negative implications as the transaction is for tax withholding purposes and not a discretionary sale of shares.
Risks
- NA
Future Outlook
NA
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes, which is common across all publicly traded companies when executive equity compensation vests. It does not provide specific insights into broader industry trends for the diagnostics or healthcare sector.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine tax-related transaction, not a discretionary sale indicating a change in management's confidence. It confirms the CEO's continued equity ownership in the company.
- Employees: No direct impact.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2021-06-01 | Grant date for 2,926 Restricted Stock Units. |
| 2022-03-03 | Grant date for 3,534 Restricted Stock Units. |
| 2023-03-06 | Grant date for 4,877 Restricted Stock Units. |
| 2024-03-06 | Grant date for 7,170 Restricted Stock Units. |
| 2025-06-02 | Transaction date for tax withholding related to RSU vesting. |
| 2025-06-04 | Signature date of the filing by attorney-in-fact. |
Recommendation
holdKeywords
Veracyte, VCYT, Marc Stapley, Form 4, SEC filing, insider transaction, stock ownership, RSU vesting, tax withholding, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.